Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that intralesional triamcinolone acetonide at both 5 mg/mL and 10 mg/mL concentrations had similar effectiveness and safety for treating patchy alopecia areata on the scalp, with no significant difference in response rates or side effects between the two dosage groups.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

This case report highlights a 33-year-old female with systemic lupus erythematosus and refractory alopecia who experienced significant hair regrowth after treatment with tofacitinib, maintained even after glucocorticoid tapering over two years.

In this study, 40% of alopecia areata patients using topical 2% tofacitinib ointment achieved greater than 50% improvement in hair regrowth after six months, showing significant efficacy compared to controls, with no serious adverse effects reported.

This study found that tofacitinib was a safe and effective treatment for patients with moderate-to-severe alopecia areata, with a significant percentage achieving notable reductions in their Severity of Alopecia Tool scores after 18 months.

This study found that the combination of letrozole and quercetin loaded in spanlastics showed enhanced cytotoxicity and other anticancer effects against MCF-7 breast cancer cells compared to individual treatments.

In this study, patients with active lymphocytic cicatricial alopecia showed significant improvement using a three-stage treatment regimen involving Tofacitinib, Apremilast, and Crisaborole, with 93.5% experiencing marked improvement and only three mild adverse events reported.

This comparative clinical study found no statistically significant difference in the remission and recurrence rates between intralesional triamcinolone acetonide and methotrexate for treating localized alopecia areata, suggesting similar efficacy between the two treatments.

This study found that reported stress and hair growth changes related to facial/body hair excess or scalp hair loss differ among ethnic gender minority groups, with black and other ethnic respondents experiencing more stress compared to Caucasians, particularly in relation to facial/body hair excess.

This study found that low-dose methotrexate significantly reduced the steroid requirement in subjects with corticosteroid-requiring asthma without altering their clinical status or causing significant complications.

The study found that both mometasone and calcipotriol ointments effectively reduced alopecia severity in localized alopecia areata, with calcipotriol having fewer side effects, while tacrolimus showed no significant effect.

This study involving 126 patients found that tofacitinib has high effectiveness and an acceptable safety profile for treating alopecia areata, with a 33.8% complete response rate at 24 weeks and sex as an independent risk factor for outcomes.

This study found that oral tofacitinib led to clinically significant improvement in alopecia areata severity scores among pre-adolescents, though results varied and further evaluation in clinical trials is needed.

This study found that combining oral isotretinoin with topical treatments was more effective than topical treatments alone for improving frontal fibrosing alopecia symptoms, despite some side effects.

In this study, tofacitinib showed significant efficacy in treating alopecia totalis and universalis over a 6-month period, with notable hair regrowth outcomes, while younger age of onset and shorter treatment duration were linked to less effectiveness.

In this phase I study, partial hair regrowth was observed in patients with alopecia universalis using topical JAK inhibitors, though more research is needed to confirm potential as a treatment alternative to clobetasol.

Tacalcitol ointment effectively improves bilateral nevus comedonicus.

This case report describes a 38-year-old patient with trichomycosis axillaris, successfully treated with shaving, 3% erythromycin cream, and clotrimazole powder.

In this study, retrospective analysis of patients with severe alopecia areata showed that oral JAK inhibitors, tofacitinib and baricitinib, reduced hair loss significantly, with comparable effectiveness; longer tofacitinib use was linked to greater improvement, while baricitinib achieved substantial outcomes quickly.

In this case report, the researchers described the use of tofacitinib in treating a 14-year-old boy from India with severe alopecia areata, achieving complete hair regrowth within 2 months without serious adverse events, highlighting tofacitinib's potential benefits and safety in adolescent cases.

This article reviews 12 newly approved drugs with pediatric indications from 2001, discussing their clinical importance for general pediatricians, but reports no new clinical results.

This source discusses the potential of topical JAK inhibitors, like tofacitinib, as effective treatments for autoimmune skin diseases, emphasizing their superior safety profile and minimal adverse effects compared to conventional systemic therapies.

This study compared intralesional betamethasone and triamcinolone acetonide for treating alopecia areata and found that both were effective, with betamethasone 1.75mg/ml showing similar results to triamcinolone at 12 weeks without adverse effects.

This abstract introduces TrichoFoam™, a new foaming vehicle for compounding pharmacies, designed to be a gentle, non-irritating option for alopecia treatment, acknowledging that current topical treatments are limited and oral products may cause adverse effects.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

This study reports significant hair regrowth in 11 patients with severe alopecia areata following longstanding treatment with oral tofacitinib and also highlights successful treatment using topical tofacitinib cream in one case.

In this study, tofacitinib and baricitinib showed comparable efficacy and tolerability under unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe alopecia areata over 24 weeks; however, the unorthodox baricitinib regimen yielded a lower effectiveness in severe cases, emphasizing the importance of adherence to guideline-recommended dosing.